Results: Over half of providers 82/151 (54%) recommend HPV vaccination always or most of the time (range: 20% in Malaysia to 90% in Argentina). Most providers 112/151 (74%) said they were comfortable recommending HPV vaccination, although South Korea was an outlier 10/30 (33%). Providers cited protection against cervical cancer 124/151 (83%) and genital warts 56/151 (37%) as benefits of HPV vaccination. When asked about the problems with HPV vaccination, providers mentioned high cost 75/151 (50% overall; range: 26% in South Africa to 77% in South Korea) and vaccination safety 28/151 (19%; range: 7% in South Africa to 33% in Spain). Free, low-cost, or publicly available vaccination 59/151 (39%), and additional data on vaccination safety 52/151 (34%) and efficacy 43/151 (28%) were the most commonly cited facilitators of health provider vaccination recommendation. Conclusion: Interventions to increase HPV vaccination should consider a country's specific provider concerns, such as reducing cost and providing information on vaccination safety and efficacy.
Introduction
Cervical cancer is the fourth most common cancer in women worldwide, with an estimated 528,000 new cases and 266,000 deaths in 2012. 1 Approximately 85% of cervical cancer cases occur in less developed regions, with high incidence in sub-Saharan Africa, South Asia, and Latin America. 1 Almost all cases of cervical cancer (99%) are attributable to human papillomavirus (HPV), a sexually transmitted infection affecting over 290 million women worldwide. 2, 3 With widespread use, prophylactic vaccination has the potential to markedly reduce the number of HPV infections, having been shown to decrease quadrivalent vaccineassociated type HPV prevalence by 77% among 18-to 24-yearolds in Australia, 4 and by 56% among 14-to 19-year-olds in the United States despite only 32% coverage. 5 HPV vaccination also has potential to reduce the number of cervical cancer cases, as well as anal, vaginal, vulvar, penile, and oropharynx cancers, of which 31%-88% of incident cases worldwide are attributable to HPV. 6 The first HPV vaccine was licensed in 2006. 7 Today, 3 HPV vaccines are available globally, depending on country: a bivalent vaccine targeting antigens for HPV types 16 and 18; a quadrivalent vaccine (adding HPV types 6 and 11) 2 ; and a nonavalent vaccine (further adding HPV types 31, 33, 45, 52, and 58) to provide protection against HPV types that cause approximately 90% of cervical cancers, as well as notable protection against vaginal, vulvar, and anal cancers. 8 The World Health
Organization's recommended target population for HPV vaccination is girls between the ages of 9 and 14 years, before sexual activity has started, with girls ages 15 and older and boys as secondary target populations. 9 Many countries recommend HPV vaccination for boys and girls. Differences in national availability of HPV vaccination has led to varying coverage rates worldwide. An estimated onethird of girls ages 10-20 years old in high-income countries had completed full-course HPV vaccination by 2014, in contrast to only 7.2%, 0.1%, and 1.0% in upper-middle income, lower-middle income, and low-income countries, respectively. 10 However, some countries have achieved enormous success in attaining high coverage rates, such as Rwanda, which has an estimated 97% full-course coverage for girls born in 2000, 11 and Malaysia, which reported 94% fullcourse coverage for 13-year-old girls in 2013. 12 Physician recommendation is one of the most important influences on the decision to become vaccinated.
13e17 Physicians can address vaccine-associated fears and hesitancy, and strongly endorse HPV vaccination. Yet quantitative global data on provider vaccination practices are relatively scarce. 18 Studies on providers' HPV vaccination recommendation practices in individual countries exist, 14, 19 including studies among health providers in Europe, which identify concerns about the vaccine's efficacy and long-term effects, provider's lack of time, and difficulty providing information to the target population of girls. 20, 21 However, none have described health provider responses across countries.
In this study, we present quantitative data from provider interviews in 5 countries (Argentina, Malaysia, South Africa, South Korea, and Spain) to assess adolescent health care providers' recommendations of and attitudes toward HPV vaccination.
Materials and Methods

Study Participants
Structured interviews were conducted face-to-face or via phone with adolescent vaccination providers between October 2013 and April 2014 using a standardized questionnaire, as previously reported. 22 Providers from Argentina, Malaysia, South Africa, South Korea, and Spain were identified via convenience sampling and recruited through mail, e-mail, phone, or in-person conversations. Specific methods included outreach to study staff contacts, review of databases from national professional organizations, national health insurance reviews, and assessments, Web sites, and lists from external consultants. Providers were considered eligible if they had ever administered or overseen provision of adolescent vaccinations, and if they were authorized to administer adolescent vaccinations according to each country's medical regulations. Because the overall purpose of the study was to assess the acceptability of 2-vs 3-dose vaccination schedules through an in-depth interview process, we aimed to recruit 30 health providers per country, consistent with previous studies of health providers' HPV vaccination perceptions.
23,24
Measures
Provider demographic characteristics and information on attitudes toward HPV vaccination were collected by a study interviewer trained in structured interviewing techniques. Interview questionnaires were adapted from previously used surveys 25e27 and newly developed items on the basis of HPV vaccination-related issues documented in the literature. Survey questions focused on the World Health Organization's HPV vaccination target group, girls ages 9-14 years, 9 substituting the lower age range bound with each country's specific guideline (Argentina: 11 years of age; Malaysia: 13; South Africa: 9; South Korea: 11; and Spain: 11). Study eligibility, consent, and survey documents were translated from English into local languages when necessary. Specific survey questions related to provider HPV vaccination recommendations are included in Appendix A.
Data Analyses
In-country study staff double-entered deidentified data into English language EpiData (EpiData Association) forms, and translated data into English when necessary. Data were cleaned and analyzed at the University of North Carolina (UNC). Frequency tabulations were conducted on: (1) provider sociodemographic characteristics; (2) the frequency at which providers recommended routine HPV vaccination; (3) provider opinions about the advantages and disadvantages of HPV vaccination; (4) reasons for not always recommending HPV vaccination; (5) provider levels of comfort and reasons for any discomfort in recommending HPV vaccination; and (6) factors facilitating HPV vaccination recommendation. Odds ratios were estimated to determine associations between provider characteristics and provider frequency of HPV recommendation, comparing recommendation always or most of the time, relative to sometimes, hardly ever, or never. We used SAS version 9.4 (SAS Institute Inc) for all analyses.
Ethical Considerations
This study was approved by the UNC Office of Human Ethics and institutional review boards in each of the 5 collaborating countries. UNC study staff received institutional review board approval for analysis of deidentified secondary data.
Results
Of 353 vaccine providers contacted, 151 enrolled in Argentina (n 5 30), Malaysia (n 5 30), South Africa (n 5 31), South Korea (n 5 30), and Spain (n 5 30; 
Reasons for Not Always Recommending HPV Vaccination
A third 26/83 (31%) of providers who do not always recommend HPV vaccination considered cost to be too high for patients or that insurance coverage was difficult to determine (range: 6% in South Africa to 48% in South Korea; 
Facilitators of HPV Vaccination Recommendation
The most commonly cited facilitator of provider recommendation of HPV vaccination was free, low-cost, or publicly available vaccination 59/151 (39%; range: 26% in South Africa to 57% in South Korea; Fig. 2 ). One-third of providers 52/151 (34%) wanted more data on vaccination safety (range: 10% in Malaysia to 80% in Spain) and 43/151 (28%) providers wanted more data on long-term vaccination efficacy (range: 3% in Malaysia to 80% in Spain). Seventeen percent 25/151 said that a school-located program would be an effective facilitator (range: 0% in Spain to 40% in South Korea). 20/151 (13%) providers desired more general information, or educational campaigns, promotions, and advertisements to facilitate recommendation of vaccination (range: 0% in Argentina to 26% in South Africa).
Provider Opinions about HPV Vaccination
Most providers 125/151 (83%) listed protection against cervical cancer as one of the benefits of HPV vaccination (range: 68% in South Africa to 97% in South Korea; Table 3 ). In addition, 56/151 (37%) providers listed protection against genital warts (range: 10% in South Korea to 83% in Spain). 23/151 (15%) considered the vaccination's long-lasting immunity and prevention of other HPV-related outcomes as beneficial (range: 7% in Spain to 20% in South Korea and South Africa). 13/151 (9%) providers cited vaccination safety and lack of adverse events as a benefit of vaccination.
Cost was considered a major disadvantage for half of providers 75/151 (50% range: 26% in South Africa to 77% in South Korea). 28/151 (19%) providers stated that HPV vaccination might be unsafe or cause adverse events (range: 7% in South Africa to 33% in Spain). Providers also expressed concerns that the vaccination does not protect against all HPV types or cervical cancers 27/151 (18%; range: 0% in Malaysia to 33% in Spain), the pain of the shot 24/151 (16%; range: 10% in South Africa to 20% in Argentina and Malaysia), and that there is not enough evidence for HPV vaccination 10/151 (7%; range: 0% in Malaysia, South Africa, and Spain to 27% in Argentina). Only 3/151 providers (2%), all of whom were from South Africa, stated that the likelihood of girls having sex would increase if vaccinated.
Comfort in Recommending HPV Vaccination and Reasons for Any Discomfort
Overall, most providers 112/151 (74%) reported being comfortable recommending vaccination, with South Korea being a low outlier 10/30 (33%; Table 3 ). Only a quarter of providers 36/151 (24%) were uncomfortable recommending vaccination. Of the 36 providers who were uncomfortable recommending vaccination, approximately half 20/36 (56%) cited high costs as a reason for discomfort (range: 0% in South Africa to 80% in South Korea). A third of providers 11/ 36 (31%) stated concerns about vaccination safety and side effects (range: 0% in Malaysia to 75% in Spain). Only 9/36 providers (25%), 7 in Korea and 2 in Malaysia, stated they were uncomfortable discussing sexual health or sexually transmitted infections.
Discussion
In our study of 151 adolescent vaccine providers we assessed frequency of routine provider recommendations for HPV vaccination in 5 countries. Protection against cervical cancer and genital warts were the most commonly cited benefits of HPV vaccination, whereas disadvantages were cost, safety, and efficacy concerns. Offering free, lowcost, or publicly available vaccination, and providing more data on safety and long-term efficacy were factors that could increase provider recommendations. Addressing specific provider concerns is of critical importance, because previous research has suggested that provider recommendation is the strongest predictor of adolescent HPV vaccination. Relatively high HPV vaccination recommendation frequencies and high levels of comfort in recommending vaccination were reported by providers from Argentina, Spain, and South Africa. Surveys of gynecologists and pediatricians in Argentina have also found high acceptability, with 82% and 75% prescribing HPV vaccination, respectively. 28, 29 Systematic reviews have consistently reported high acceptability of HPV vaccination in sub-Saharan Africa among adolescent girls, women, parents, and health care providers. 30, 31 Adolescent providers from South Korea and Malaysia in our study recommended vaccination at a relatively lower frequency than the overall group. Low recommendation frequencies in these Asian countries aligns with other research from South Korea, Thailand, Taiwan, and Malaysia, where only 56% of physicians had initiated conversations regarding HPV vaccination, and a third of these providers reported discomfort in doing so. 13 In Malaysia and in the study region of Spain, vaccinations are systematically administered through school-located programs, yet in our study only 3/30 (10%) providers in Spain and 1/30 (3%) provider from Malaysia administered vaccines in schools.
Results might have differed if interviews had been limited to school-located providers, particularly in Malaysia, where the rate of full-course HPV vaccination completion is high. 12 Cost of HPV vaccination in Malaysia is substantial for girls not covered under school programs, which might also partially explain provider hesitancy (Dr Karen Morgan, written communication, November 2017). Because the study sample represents a larger catchment of adolescent health care providers, results could provide insight into efforts to increase vaccination uptake in other regions that use a clinicbased approach or in countries that supplement schoollocated programs with clinic-based HPV vaccination. In our study, protection against cervical cancer and genital warts were the most frequently cited advantages of HPV vaccination, consistent with literature from Malaysia, where over 95% of providers agreed that HPV vaccines can prevent cervical cancer, 14 and in India, where 81% of surveyed health care professionals were aware that vaccination prevents cervical cancer. 19 Concern about cost was the most frequently cited disadvantage of HPV vaccination among providers within each country. Similarly, cost was the most important consideration in willingness to vaccinate among health care providers in Vietnam, which does not have a routine HPV Fig. 2 . Factors that would facilitate provider recommendation of human papillomavirus vaccination (N 5 151). Percentages might sum to more than 100, because of the possibility of multiple responses. CI, confidence interval; HPV, human papillomavirus; NGO, nongovernmental organization; OB/GYN, obstetrician/gynecologist. * Excluding 10 observations because of missing data on frequency of provider recommendation.
y All odds ratios are calculated for provider HPV vaccine recommendations "always/most of the time" relative to "sometimes/hardly ever/never." z Other provider types include caregiver, health promotion practice, schoollocated nurse, and preventive medicine.
x N 5 138, excluding 3 additional observations because of missing data (n 5 2) and an outlier.
immunization program. 32 Over a third (59/151) of providers in our study cited free, low-cost, or publicly available vaccination, and more data on vaccination safety (52/151) as factors that would facilitate vaccination recommendation. South Korea has already moved to address cost by including HPV vaccination in the National Immunization Program since 2016 and offering 2 doses of either the bivalent and quadrivalent vaccine for free to girls and boys younger than the age of 12 years. 33 Several countries have also achieved high coverage rates by offering the vaccination through school-based programs, simultaneously reducing cost and increasing accessibility for greater coverage of the target population. 34 Providers in our study do not always recommend HPV vaccination because of a lack of time, particularly in Malaysia and South Korea. Likewise, in another study among 480 physicians across 4 countries in Asia, the most common impediments included the perceived time-consuming nature of a discussion about Vaccination would not reduce need for routine cervical cancer screening/requires providers to discuss sexual health issues with girls and/or parents 20 0 3 0 20 9
Negative perceptions/lack of parental support/need better awareness and/or education campaigns Data are presented as percentages. HPV, human papillomavirus. * Percentages might sum to more than 100, because of the possibility of multiple responses.
HPV vaccination with parents. 13 Twenty-one percent of physicians from the same study thought that HPV vaccination is a sensitive subject that parents might object to discussing, and 16% found it difficult to know how and when to initiate the discussion. In contrast, very few providers in our study cited difficulty in discussing sexual issues with parents of girls as a reason why they do not always recommend HPV vaccination. Research in Malaysia has shown that among 247 HPV vaccination providers, members of certain ethnic groups were more likely to view cultural sensitivity as an issue in HPV vaccination recommendation, because HPV infection is sexually transmitted. 14 The level of hesitation to discuss sexual issues with parents might vary depending on the culture in which a provider practices. Regarding additional barriers, adolescent providers in our study said they do not always recommend vaccination because of a lack of evidence, insufficient information, or that the vaccination is not effective, safe, or useful. These cited disadvantages align with research in Europe among health care professionals, which reported fear of adverse side effects and vaccination safety, poor information, and perceived ineffectiveness were all reasons for provider hesitancy. 35 Vaccination-related side effects occurring during receipt of HPV vaccination in European countries received national attention and programmatic change, leading to physician doubts about vaccination safety. 36 Provider attitudes toward vaccination have wide-reaching influence on uptake; advice by a nurse or physician whether positive or negative, was a primary source of association with the vaccination status of girls in Spain. 37 National HPV vaccination availability at the time of our survey might have influenced provider recommendation practices. In Argentina, Malaysia, and Spain, HPV vaccination became part of the National Immunization Program under Ministry of Health recommendations for adolescent females in 2011, 2010, and 2007, respectively, before the start of our study. 29 Study results highlight specific provider concerns that can be targeted through programmatic efforts to increase the quantity and frequency of routine provider recommendations. Making education a priority for health care providers before HPV vaccination is widely available is recommended to increase understanding of the vaccination's benefits and limitations, and to encourage provider discussions with patients. 43 In a study of 427 health care providers in the United States, the HPV knowledge score of providers increased after attending an educational lecture, 44 and further research among American College of Obstetricians and Gynecologists fellows showed that physicians who responded accurately about protective benefits were more likely to administer the HPV vaccination. 45 Among 480 Asian physicians surveyed, two-thirds said that a recommendation of HPV vaccination from the Ministry of Health or the government would facilitate their own recommendation that mothers vaccinate their daughters during the next year, 13 iterating the role of policymakers in promoting physician recommendation. The primary strength of our study is the aggregation of provider HPV vaccination recommendation data across 5 countries. Although previous studies have considered provider recommendations in individual countries or compared ethnic groups within the United States, 46 to our knowledge, none to date have systematically described results from different countries. Including providers who frequently and rarely recommend HPV vaccination offers a wide range of perspectives on barriers and facilitators. One study limitation stems from the relatively small sample sizes within each country; the group of providers surveyed might not be representative of all adolescent vaccination providers within each country. Conclusions comparing individual sites should be interpreted with caution because of differences in cultural context, timing of vaccination introduction, as well as other unmeasured factors. Another limitation is that our study did not capture information on the strength and quality of provider recommendations. Previous research has shown that behavior changes such as making presumptive statements that assume parental readiness to vaccinate, taking an active role in the vaccination decision, and giving a high-quality recommendation to parents increases HPV vaccination uptake. 18, 47, 48 Survey questions focused on provider recommendations and provider attitudes toward HPV vaccination among adolescent girls specifically, although findings are also likely to apply to provider recommendations for adolescent boys. Although this study focused on HPV vaccination among adolescents given the vaccination results in optimal protection before exposure, 49 vaccination of pregnant mothers might also result in antibodies to prevent vertical transmission of HPV. 50 Our study reports globally relevant data on provider HPV vaccination recommendations. Because provider recommendation is one of the principal factors that motivate vaccination uptake, programs and research should focus on reducing barriers and enhancing the facilitators that providers identify to recommending HPV vaccination. Organizations are currently working to increase the frequency and quality of HPV vaccination recommendations, including the National HPV Vaccination Roundtable, 51 which has created HPV vaccination action guides for health systems, private practices, physicians, and other health care providers. The American Cancer Society has also created a guidebook for clinicians that uses evidence-based strategies to increase HPV vaccination. 52 Other professional organizations such as 
